| Literature DB >> 34367299 |
Haizhen Lu1, Chengwen Zheng1, Yanmei Zhong2, Linhao Cheng3, Yi Zhou1.
Abstract
BACKGROUND: Hyperemesis gravidarum (HG) is a common gastrointestinal disease afflicting gravidas. It usually results in hospital admission in early pregnancy.Entities:
Year: 2021 PMID: 34367299 PMCID: PMC8337134 DOI: 10.1155/2021/2731446
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
PubMed search strategy.
| No. | Searches |
|---|---|
| #1 | Hyperemesis Gravidarum [MeSH] |
| #2 | Pernicious Vomiting of Pregnancy [title/abstract] |
| #3 | Pregnancy Pernicious Vomiting [title/abstract] |
| #4 | #1 OR #2 OR #3 |
| #5 | Acupuncture [MeSH] |
| #6 | Acupuncture Therapy [MeSH] |
| #7 | Acupuncture Points [MeSH] |
| #8 | #5 OR #6 OR #7 |
| #9 | Acupuncture [title/abstract] |
| #10 | Acupuncture treatment ∗ [title/abstract] |
| #11 | Acupuncture therap ∗ [title/abstract] |
| #12 | Pharmacopuncture [title/abstract] |
| #13 | Pharmacoacupuncture treat ∗ [title/abstract] |
| #14 | Electroacupunctur ∗ [title/abstract] |
| #15 | Electro-acupunctur ∗ [title/abstract] |
| #16 | Acupoint ∗ [title/abstract] |
| #17 | Acupotom ∗ [title/abstract] |
| #18 | Point∗, Acupuncture [title/abstract] |
| #19 | Meridian ∗ [title/abstract] |
| #20 | Moxibustion [title/abstract] |
| #21 | #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 |
| #22 | #8 OR #21 |
| #23 | Randomized controlled trial [publication type] |
| #24 | Randomized [title/abstract] |
| #25 | Placebo [title/abstract] |
| #26 | #23 OR #24 OR #25 |
| #27 | #4 AND #22 AND #26 |
Statement of participants, interventions, comparisons, outcomes, and study design (PICOS).
| Participants ( | Patients diagnosed with HG. |
|
| |
| Interventions ( | The treatment group received the common forms of acupuncture solely or combined with other treatments, regardless of acupoint selection, treatment frequency, or course. |
| The control group adopted conventional symptomatic treatment, conventional medication, placebo, sham, or no treatment. | |
| The two groups could receive the same basic treatment. | |
|
| |
| Comparisons ( | The control group adopted conventional treatment, medication, placebo acupuncture, sham acupuncture, or no treatment. |
|
| |
| Outcomes ( | The effective rate, conversion rate of urine ketone, symptom improvement rate, serum potassium, hospital stay, pregnancy termination rate, adverse events, and recurrence. |
|
| |
| Study design ( | RCT. |
Figure 1PRISMA flow diagram.
Characteristics of included studies (1).
| Study | Year | Country | Study period | Age (years) (mean ± SD) | Gestational age (weeks) (mean ± SD) | ||
|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||
| Habek et al. [ | 2004 | Croatia | — | 20.4 ± 4.7 | 20.8 ± 4.1 | 7 (6–9)∗ | 8 (7–12)∗ |
| Neri et al. [ | 2005 | Italy | 2001.5–2002.7 | — | — | — | — |
| Jin and Hu [ | 2014 | China | 2009.10–2013.10 | 25.09 ± 3.42 | 26.03 ± 3.19 | 9.03 ± 2.15 | 8.98 ± 2.28 |
| Ma et al. [ | 2020 | China | 2013.10–2017.10 | 31.14 ± 4.06 | 31.36 ± 4.24 | 8.64 ± 1.22 | 8.36 ± 1.31 |
| Wang [ | 2008 | China | 2005.1–2006.1 | 27 ± 3 | 27 ± 4 | — | — |
| Ma and Meng [ | 2013 | China | 2010–2012 | 26.30 | — | — | |
| Zhao and Qiao [ | 2018 | China | 2015.4–2017.11 | 26 ± 3 | 26 ± 3 | 8.33 ± 1.94 | 8.03 ± 1.63 |
| Zhang [ | 2013 | China | 2008.1–2012.12 | 28.58 ± 4.57 | 28.68 ± 3.76 | 8.90 ± 1.66 | 8.97 ± 1.58 |
| Yan et al. [ | 2012 | China | 2008.1–2009.6 | 28.09 ± 5.78 | 28.03 ± 6.25 | 9.08 ± 2.44 | 8.95 ± 2.58 |
| Xu et al. [ | 2015 | China | 2013.1–2014.10 | (20–35)# | (4–12)# | ||
| Sun and Cui [ | 1995 | China | 1992.1–1994.12 | (22–34)# | — | — | |
| Yang [ | 2019 | China | 2016.11–2018.11 | 31.56 ± 6.25 | 31.42 ± 6.37 | 8.52 ± 3.62 | 8.86 ± 3.57 |
| Zhong [ | 2017 | China | 2015.9–2016.9 | 28.35 ± 2.76 | 27.93 ± 2.47 | — | — |
| Xie [ | 2006 | China | 2004.1–2005.5 | 27.25 ± 3.35 | 27.46 ± 3.29 | — | — |
| Mao and Liang [ | 2009 | China | 2001.1–2008.12 | 28.23 ± 4.73 | 28.63 ± 4.86 | 8.30 ± 1.60 | 8.33 ± 1.58 |
| Zhang [ | 2005 | China | 1999.3 | — | — | — | — |
Abbreviation: SD: standard deviation; T: treatment group; C: control group; ∗: figures are median and range; #: figures are a range.
Characteristics of included studies (2).
| Study | Intervention | Number of patients ( | Intervention period | Relevant outcomes | Study type | |
|---|---|---|---|---|---|---|
|
|
| |||||
| Habek et al. [ | AP | Placebo acupuncture | 18 (10/8) | Over 7 days | ② | RCT |
| Neri et al. [ | AP + acupressure | Metoclopramide | 81 (43/38) | 14 days | ④⑩⑪ | RCT |
| Jin and Hu [ | AP + ① | ① | 40 (20/20) | Lasted for 5 days | ②③⑦⑧⑨ | RCT |
| Ma et al. [ | AP + ① | ① | 72 (35/34) | Lasted for 7 days | ②③④⑤⑥ | RCT |
| Wang [ | AP | ① | 95 (53/42) | Lasted for 6 days | ②⑧⑨ | RCT |
| Ma and Meng [ | AP + TNA | TNA | 60 (30/30) | Lasted for 5 days | ② | RCT |
| Zhao and Qiao [ | AP + acupoint sticking | ① | 60 (30/30) | Lasted for up to 7 days | ② | RCT |
| Zhang [ | AP + ① + psychological counseling | ① | 62 (31/31) | Lasted for 7 days | ② | RCT |
| Yan et al. [ | AP + ① | ① | 64 (32/32) | (3.12 ± 0.25) days/(6.32 ± 0.12) days | ②⑦⑬ | RCT |
| Xu et al. [ | AP + moxibustion + ① | ① | 70 (35/35) | Unknown | ② | RCT |
| Sun and Cui [ | AP + ① | ① | 40 (20/20) | Lasted for 3 days | ② | RCT |
| Yang [ | AP + ① | ① | 60 (30/30) | Unknown | ②⑫ | RCT |
| Zhong [ | AP + ① | ① | 70 (35/35) | Unknown | ② | RCT |
| Xie [ | AP + ① | ① | 94 (47/47) | Lasted for 10 days | ②③④⑤⑥ | RCT |
| Mao and Liang. [ | AP + ① | ① + oral luminal 30 mg, tid | 60 (30/30) | Lasted for 7 days | ② | RCT |
| Zhang [ | AP + moxibustion | ① + oral luminal 30 mg, tid | 100 (50/50) | 14 days | ② | RCT |
Abbreviation: T: treatment group; C: control group; RCT: randomized controlled trial; AP: acupuncture; TNA: total nutrient admixture; tid: three times a day; ①: symptomatic rehydration support treatment; ②: effective rate; ③: conversion rate of urine ketone; ④: improvement rate of food intake; ⑤: improvement rate of lassitude symptom; ⑥: improvement rate of nausea and vomiting symptom; ⑦:length of hospital stay; ⑧: serum potassium; ⑨: pregnancy termination rate; ⑩: improvement rate of nausea intensity; ⑪: improvement rate of vomiting episodes; ⑫: adverse events rate; ⑬: recurrence rate.
Figure 2Diagram of the bias risk.
Figure 3Summarized bias risk.
Figure 4Outcomes of the meta-analysis for the influence of effective rate.
Figure 5Resultants of a meta-analysis for the affection of the conversion rate of urine ketone.
Figure 6The meta-analysis results of the improving rate effects of nausea and vomiting symptoms.
Figure 7The meta-analysis results of improvement rate effects of food intake.
Figure 8Sensitivity of the improvement rate of food intake (Galbraith).
Figure 9The re-meta-analysis results of the improving rate effects of food intake.
Figure 10The meta-analysis outcomes of the amelioration rate of lassitude symptom.
Figure 11The meta-analysis outcome of the influence study of serum potassium.
Figure 12The meta-analysis outcome of the interactions of the length of hospital stay.
Figure 13The meta-analysis outcome of pregnancy termination incidence.
Figure 14Publication bias of the effective rate.